Oncology

MM41 targets cell nuclei to provide a new method of attacking pancreatic cancer.

Nivolumab and ipilmumab help immune system to shrink tumors.

Restoration of miR-29 in cancer stromal cells helped decrease cancer growth.

Treatment could make existing cancer drugs more effective.

The impact of products such as orange juice on melanoma.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients.

There are currently more than 600 trials of biosimilars ongoing.

Hormones that reduce side effects may stimulate growth of cells resistant to therapy.

Combination of immunotherapy and epigenetics put patients into remission, even after failing the standard treatment.

Size and speed of tumor growth similar in dogs and humans.

Small molecule agent able to detect or destroy prostate cancer cells when combined with different radionuclides.

Researchers discuss mechanism for overcoming resistance to drugs that target BRAF protein.

Increasing immune cell infiltration into tumors induces the immune system to block tumor growth.

Lipid from avocados targets leukemia stem cells.

Necitumumab added to chemotherapy increases survival to nearly a year.

Many patients experience distress from concerns over treatment and disease progression.

New cases have increased by nearly 50% over last 30 years.

Duration of sleep and snoring may play a role in survival outcomes.

Early palliative care reduces costs more than traditional treatment standards.

Promacta is the first and only oral thrombopoietin-receptor agonist that increases platelet production.

Increasing number of urology practices working with specialty pharmacies.

Men with AR-V7 variant more likely to be resistant to hormone drugs.

Drug is being evaluated for the treatment of patients who received at least 3 prior lines of therapy.

Glioblastoma treatment with surgical resection may benefit patients with worst prognoses.

Undertreated side effects in treatment of some colon and stomach cancers need to be addressed.

Recently published data from a survey of commercial health plans reveal the latest trends and emerging strategies in oncology management.